Late follow-up of a randomised trial of surgery plus tamoxifen versus tamoxifen alone in women over 70 with operable breast cancer

Fennessy, M., Bates, Tom, MacRae, K., Riley, C., Houghton, J., Baum, M. (2004) Late follow-up of a randomised trial of surgery plus tamoxifen versus tamoxifen alone in women over 70 with operable breast cancer. British Journal of Surgery, 91 . pp. 699-704. (doi:10.1002/bjs.4603) (Access to this publication is currently restricted. You may be able to access a copy if URLs are provided)

Abstract

Three hundred and eighty-one women with operable breast cancer aged over 70 years were randomly allocated to 40 mg tamoxifen daily and optimal surgery or to tamoxifen alone. At a median follow-up of 34 months there was no demonstrable difference in survival rate or in quality of life between the two treatment groups. More patients treated with tamoxifen alone had a subsequent change of management and this was usually an operation for local treatment failure. This progression to surgery has not been shown to be disadvantageous and the study will continue. Informed consent for randomization was difficult to obtain, leading to the exclusion of eligible patients, and it is therefore proposed to include non-randomised patients in a total cohort study.

Item Type:	Article
DOI/Identification number:	10.1002/bjs.4603
Subjects:	R Medicine > RD Surgery R Medicine
Divisions:	Faculties > Social Sciences > Centre for Professional Practice
Depositing User:	Tom Bates
Date Deposited:	29 Jun 2011 13:20 UTC
Last Modified:	28 May 2019 15:13 UTC
Resource URI:	https://kar.kent.ac.uk/id/eprint/23631 (The current URI for this page, for reference purposes)
Bates, Tom:	https://orcid.org/0000-0001-5554-1945